A common cognitive disorder with symptoms that mimic Alzheimer's is often mistaken for the disease. Researchers are calling for criteria to diagnose the little-known condition.

Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion centers.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

Xenon gas, currently used in medicine as an anesthetic and neuroprotective agent for treating brain injuries, showed potential in protecting the brain in studies.

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Researchers uncover promising evidence that xenon gas, commonly used in anesthesia, may help reduce brain deterioration and ...

Amneal Pharmaceuticals has received approval from the Food and Drug Administration for a dementia treatment and a drug targeting certain types of brain tumors, as well as tentative approval for a drug ...

Aerobic exercise significantly lowers Alzheimer’s disease markers and improves brain health, offering a promising preventive ...

New research suggests that commonly used medications like antibiotics, antivirals, and anti-inflammatories could lower the ...